Viatris Xalabrands — Net Sales decreased by 6.7% to $39.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.7%, from $37.10M to $39.20M. Over 4 years (FY 2021 to FY 2025), Xalabrands — Net Sales shows a downward trend with a -8.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful market penetration or pricing power for these specific products, while a decrease may indicate market saturation, generic competition, or a planned phase-out of the product line.
This metric represents the total revenue generated from the sale of the Xalabrands product portfolio after accounting fo...
Similar to revenue reporting for legacy brand portfolios or non-core product segments at other large-cap pharmaceutical companies.
vtrs_segment_xalabrands_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $58.30M | $55.80M | $54.00M | $53.00M | $42.70M | $51.00M | $48.40M | $46.70M | $50.40M | $47.90M | $48.20M | $42.50M | $45.60M | $41.20M | $37.10M | $37.10M | $40.70M | $38.60M | $42.00M | $39.20M |
| QoQ Change | — | -4.3% | -3.2% | -1.9% | -19.4% | +19.4% | -5.1% | -3.5% | +7.9% | -5.0% | +0.6% | -11.8% | +7.3% | -9.6% | -10.0% | +0.0% | +9.7% | -5.2% | +8.8% | -6.7% |
| YoY Change | — | — | — | — | -26.8% | -8.6% | -10.4% | -11.9% | +18.0% | -6.1% | -0.4% | -9.0% | -9.5% | -14.0% | -23.0% | -12.7% | -10.7% | -6.3% | +13.2% | +5.7% |